Staging Concordance and Guideline-Concordant Treatment for Esophageal Adenocarcinoma

Ann Thorac Surg. 2022 Jan;113(1):279-285. doi: 10.1016/j.athoracsur.2020.12.046. Epub 2021 Jan 20.

Abstract

Background: Treatment selection for patients with esophageal adenocarcinoma is predicated on clinical staging information, which is inaccurate in 20% to 30% of cases and could impact the delivery of guideline-concordant treatment. We aimed to evaluate the association between staging concordance at the patient and hospital levels with the delivery of guideline-concordant treatment among esophageal adenocarcinoma patients.

Methods: This was a national cohort study of resected esophageal adenocarcinoma patients in the National Cancer Data Base (2006 to 2015) treated either with upfront resection or neoadjuvant therapy followed by surgery. Patient- and hospital-level clinical and pathologic staging concordance and deviations from treatment guidelines were ascertained. For neoadjuvant therapy patients, staging concordance was predicted through Bayesian analysis. Reliability adjustment was used when evaluating hospital-level concordance.

Results: Among 9393 esophageal adenocarcinoma patients treated at 927 hospitals, 41% had upfront surgery. Among upfront surgery patients, staging concordance was 85.1% for T1N0 and 86.9% for T3-T4N+ disease, but less than 50% for all others. Among patients treated with neoadjuvant therapy, treatment downstaging was observed in 33.9%. Deviations from treatment guidelines were identified in 38.5% of upfront surgery patients and 3.3% of neoadjuvant therapy patients. The proportion of concordantly staged patients ranged from 60.1% to 87.9%, and deviations from treatment guidelines were observed among 14.9% to 22.7% of the patients. Patient staging concordance increased, and deviations from guidelines decreased, as hospital-level concordance increased (trend test, P values less than .001 for all).

Conclusions: Deviations from treatment guidelines in esophageal adenocarcinoma patients appear to be a function of inaccurate clinical staging information, which should be a new focus for quality improvement efforts.

MeSH terms

  • Adenocarcinoma / pathology*
  • Adenocarcinoma / therapy*
  • Cohort Studies
  • Combined Modality Therapy
  • Esophageal Neoplasms / pathology*
  • Esophageal Neoplasms / therapy*
  • Humans
  • Neoplasm Staging
  • Practice Guidelines as Topic

Supplementary concepts

  • Adenocarcinoma Of Esophagus